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INTRODUCTION
Cerebral palsy (CP) is a group of non-progressive dis-
orders characterized with an abnormal control of move-
ment and posture, and it is diagnosed most frequently in 
early childhood. Adults with CP often suffer from move-
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Deep brain stimulation (DBS) in internal globus pallidus is considered to be a good option for controlling 
generalized dystonia in patients with this condition. In this relation, it is known that DBS has already been shown 
to have significant effects on primary dystonia, but is seen as controversial in secondary dystonia including 
cerebral palsy (CP). On the other hand, intrathecal baclofen (ITB) has been known to reduce spasticity and 
dystonia in patients who did not respond to oral medications or botulinum toxin treatment. Here, we report a 
patient with dystonic CP, who received the ITB pump implantation long after the DBS and who noted remarkable 
improvement in the 36-Item Short Form Health Survey, Dystonia Rating Scale, Modified Barthel Index, and visual 
analog scale scores for pain after an ITB pump implantation was used as compared with DBS. To our knowledge, 
the present case report is the first to demonstrate the effects of an ITB pump on reducing pain and dystonia and 
improving quality of life and satisfaction, compared with DBS in a patient with CP.
Keywords  Dystonia, Intrathecal baclofen pump, Deep brain stimulation, Cerebral palsy
Received August 23, 2018; Accepted October 1, 2018
Corresponding author: Sung-Rae Cho
Department of Rehabilitation Medicine, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodamun-gu, Seoul 03722, Korea. Tel: +82-2-2228-
3715, Fax: +82-2-363-2795, E-mail: srcho918@yuhs.ac
ORCID: Minji Chae (http://orcid.org/0000-0002-0590-2113); Seungbeen Hong (http://orcid.org/0000-0002-8222-2920); Na Young Jung (http://orcid.
org/0000-0001-9996-1378); Won Seok Chang (http://orcid.org/0000-0003-3145-4016); Sung-Rae Cho (http://orcid.org/0000-0003-1429-2684).
 This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/
licenses/by-nc/4.0) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright © 2019 by Korean Academy of Rehabilitation Medicine
Minji Chae, et al.
336 www.e-arm.org
ment disorders and postural problems due to involuntary 
muscle contractions. Although CP is not a progressive 
disorder, movement symptoms such as spasticity, dyski-
nesia, and dystonia cause chronic pain, affect functional 
level, and can significantly degrade the patient’s quality 
of life.
As has been seen, dystonia is often found in CP mixed 
with spasticity, where it is referred to as ‘mixed’ tone. 
Damage of the extrapyramidal system, which occurs by 
hypoxic brain damage or kernicterus, can cause dystonia 
in some affected CP patients. To this end, dystonic CP 
patients frequently have musculoskeletal deformity and 
pain over time due to spasticity and dystonia. There are 
several types of treatment for dystonic movement in CP 
patients such as oral medications, botulinum toxin treat-
ment, intrathecal baclofen (ITB) treatment, and deep 
brain stimulation (DBS). However, there is currently a 
lack of consensus regarding the better approach for the 
treatment and pain management going forward in CP pa-
tients with severe dystonia.
It is noted that in this context, DBS in the internal glo-
bus pallidus (GPi) has been known as a good treatment 
option for controlling generalized dystonia. Although 
DBS has a significant effect on primary dystonia, it is 
controversial on noting a patient’s secondary dystonia in-
cluding CP [1]. On the other hand, an ITB treatment has 
been known as a treatment to reduce spasticity that is not 
effective in the case of using oral medications or botuli-
num toxin treatment. Many studies of ITB treatment have 
also reported significant decreases in dystonia as seen in 
some affected patients [2,3].
Here, we report a patient with dystonic CP, who re-
ceived the ITB treatment long after the DBS. This patient 
did not respond to oral medications and botulinum toxin 
treatment and was treated initially with DBS and subse-
quently with ITB therapy. The present case report is the 
first to demonstrate the effects of ITB treatment on reduc-
ing pain and dystonia and improving the patient’s quality 
of life and satisfaction as compared with DBS in a patient 
with dystonic CP.
CASE REPORT
A 35-year-old female patient visited to the department 
of rehabilitation medicine presenting with posterior neck 
pain and right upper extremity pain combined with se-
vere dystonia. Upon a review of the patient’s medical his-
tory, it is noted that she was diagnosed with CP at the age 
of one. She has experienced severe dystonia especially 
in her neck and both upper extremities; Dystonia Rating 
Scale (DRS) score was 66 points on the dystonia move-
ment scale and 19 points on the disability scale. Spastic-
ity was identified as grade 2 in the right upper extremity, 
grade 1+ in left upper extremity, and grade 1 in both 
lower extremities on the Modified Ashworth Scale (MAS). 
The patient had noted a measurement of 53 points on 
the Modified Barthel Index (MBI). She also suffered from 
pain in her posterior neck and both shoulders with a vi-
sual analog scale (VAS) score of 8. Although she had been 
treated previously with oral medication and botulinum 
toxin injection, those treatments resulted in no reduction 
in the severity of the patient’s pain and dystonia.
To exclude whether she had genetic primary dystonia, a 
fragment analysis was performed on the DYT1 gene, and 
the GAG deletion was not observed at that time. There 
were no corroborating symptoms and no abnormal re-
sults in blood tests and urinalyses to indicate the pres-
ence of Wilson’s disease in the patient. Additionally, the 
brain magnetic resonance imaging showed no notable 
findings, but it is noted that fluorodeoxyglucose uptake in 
a positron emission tomography was slightly decreased 
in the right hemisphere.
This patient received DBS in the consultation with the 
neurosurgeons. The target position of DBS electrode 
implantation on both GPi was confirmed through plain 
skull X-ray and brain computed tomography scan after 
surgery (Fig. 1). In this case, the therapeutic outcomes 
were assessed as DRS, MBI, 36-Item Short Form Health 
Survey (SF-36), and VAS scores after receiving DBS on the 
GPi. On the dystonia movement scale of the DRS, the pa-
tient scored 66 before DBS, but 3, 6, and 12 months later, 
she scored 72. Six years later, the patient scored 75, which 
was worse than her pre-DBS state. On the disability scale 
of the DRS, it is noted that the patient scored 19 before 
DBS, 27 one year after DBS, and 22 six years after DBS 
(Table 1). In activities in daily living (ADL), the patient’s 
MBI score gradually decreased and she showed persis-
tent deterioration in functional level after DBS (Table 2). 
In spasticity, the right upper extremity was scored a grade 
3, the left upper extremity scored a grade 3, and both the 
lower extremities a grade 1+ on the MAS, all of which was 
an increase over the pre-DBS state.
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Seven years after the DBS, the patient was given a 50-µg 
ITB bolus injection to assess the response to treatment 
and the presence of adverse events. Broadly speaking, the 
patient’s dystonia movement scale and pain in the poste-
rior neck and both shoulders were all markedly reduced 
after treatment with ITB (Table 1). Likewise, after a 75-µg 
ITB bolus injection to further evaluate functional change, 
the patient could not stand without assistance due to ex-
cessively reduced muscle tone in her lower extremities. 
Later, an ITB catheter infusion test trial was performed to 
decide ITB pump implantation, which was effective in re-
ducing spasticity, pain, and dystonia in the patient. There 
Table 1. Changes in dystonia rating scale score after DBS and ITBP
Dystonia rating 
scale
Pre-
DBS
Post-DBS ITB test 
trial
Post-ITBP
3 mo 6 mo 12 mo 24 mo 72 mo 3 mo 6 mo 12 mo 24 mo
Dystonia movement 
scale
66 72 72 72 70 75 64.5 63 63 65 64
Disability scale 19 20 26 27 25 22 23 23 21 19 20
DBS, deep brain stimulation; ITB, intrathecal baclofen; ITBP, intrathecal baclofen pump implantation.
Table 2. Changes in the MBI score after DBS and ITBP
MBI Pre-DBS
Post-DBS ITB 
test trial
Post-ITBP
6 mo 72 mo 6 mo 12 mo 24 mo
Personal hygiene 0 0 0 0 0 0 0
Bathing self 0 0 0 0 0 0 0
Feeding 0 0 0 5 2 2 2
Toilet 0 0 0 2 2 2 2
Stair climbing 10 0 0 8 8 5 5
Dressing 2 2 0 0 2 2 2
Bowel control 8 8 8 8 8 8 8
Bladder control 8 8 8 8 8 8 8
Ambulation 15 8 3 12 12 12 12
Chair/bed transfer 12 8 8 12 12 12 12
Total 53 34 27 55 54 51 51
MBI, Modified Barthel Index; DBS, deep brain stimulation; ITB, intrathecal baclofen; ITBP, intrathecal baclofen pump 
implantation.
A
B
Fig. 1. Plain skull X-ray (A) and 
brain computed tomography scan 
(B) showing a deep brain stimula-
tion electrode located on the in-
ternal globus pallidus bilaterally.
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was also remarkable improvement in the MBI score with-
out excessive reduction of muscle tone in the patient’s 
lower extremities (Table 2).
An ITB pump implantation was performed in this pa-
tient who showed a definitive positive response to the 
ITB test trials and also experienced no adverse events. 
To further control the spasticity of her upper extremity, 
an intrathecal catheter tip was applied up to the level of 
T5. After the procedure of the pump implantation, the 
patient was started at a dose of 50 µg ITB, which was 
gradually increased to 130 µg. On the dystonia movement 
scale, the patient scored 72 before ITB pump implanta-
tion, but 3 months later, she scored 63. Two years later, it 
is noted that the patient scored 64, which demonstrates 
a marked reduction of dystonia. On the disability scale, 
the patient scored 22 before the ITB pump implantation, 
but 2 years later, she scored 20, which represented a mild 
reduction of disability (Table 1). The patient’s ADL score 
was also improved in the MBI after the ITB pump implan-
tation compared to pre-ITB state (Table 2). In particular, 
although it was recorded that the patient had severe pain 
in her posterior neck and shoulders with a VAS score of 
8 before the ITB pump implantation, the pain decreased 
to VAS score of 1 after the pump implantation (Table 3). It 
is noted that the post-ITB pump satisfaction scores were 
remarkably higher as compared to the post-DBS satisfac-
tion scores for all items of the SF-36 (Table 3).
DISCUSSION
Management of dystonia in CP is important because 
dystonia can impair motor function, cause pain, and 
reduce independency of daily activities in the patients 
affected with this condition. Dystonia is classified as 
primary dystonia, which is caused by hereditary or un-
known factors, and secondary dystonia, which can be 
caused by brain injury or Wilson’s disease. For primary 
dystonia, DBS in the GPi is known to be an effective treat-
ment. However, DBS appears to be not so effective for the 
treatment of secondary dystonia in most cases  [1]. When 
this patient received DBS, the ITB treatment was not uni-
versal because it was not covered as a qualified condition 
reimbursed by the patient’s applicable National Health 
Insurance Service, South Korea. Based on a previous 
study [4] which reported a therapeutic effect of bilateral 
pallidal DBS on CP patients with dystonia-choreoatheto-
sis, we tried a DBS treatment in this patient with dystonic 
CP. However, the DRS and MBI scores showed a dete-
rioration after DBS in this patient, although there were 
no other factors that were known that would worsen this 
patient’s functional status. Even if the exact mechanism 
has not been yet elucidated, our previous experience [5] 
demonstrated that the disability scale was not changed or 
functionally aggravated after DBS in CP patients with dys-
tonia, whereas the DRS dramatically improved after DBS 
in primary dystonia. Andrews et al. [6] also suggested the 
existence of an incident of irreversible anatomical lesions 
in patients with secondary dystonia, which may lower the 
response to DBS. Therefore, an ITB trial should be con-
sidered in patients with CP who did not respond to oral 
medications or botulinum toxin injection rather than the 
utilization of a DBS treatment when severe spasticity and 
secondary dystonia coexist in the patient’s condition.
Narayan et al. [7] first introduced the beneficial use of a 
continuous infusion of ITB for intractable axial dystonia 
treatment. The mechanism of baclofen in treating dys-
tonia remains unclear, although it is seen that this drug 
may act both on spinal cord level and cortical level. In 
general, baclofen, a gamma-aminobutyric acid (GABA) 
agonist, selectively acts on GABA-B receptors in the brain 
Table 3. Comparison of the patient’s responses to DBS 
and ITBP
Post-DBS Post-ITBP
Pain (VAS) 8 1
SF-36
   Physical functioning 0 50
   Role limitations due to 
      physical health
0 75
   Bodily pain 22.5 67.5
   General health 60 70
   Vitality 12.5 62.5
   Social functioning 25 100
   Role limitations due to 
      emotional problems
0 100
   Emotional well being 15 75
   Physical component score 20.63 65.63
   Mental component score 13.13 84.38
DBS, deep brain stimulation; ITBP, intrathecal baclofen 
pump implantation; VAS, visual analog scale; SF-36, 
Short Form 36 Health Survey version 2.
Outcomes of Intrathecal Baclofen Therapy in Cerebral Palsy
339www.e-arm.org
and the dorsal grey matter of the spinal cord. Then, it is 
noted that the calcium influx is restricted to the presyn-
aptic terminal, which inhibits the secretion of presynaptic 
neurotransmitter. It also affects the postsynaptic terminal 
by the decreasing neuronal activity by increasing the po-
tassium flow [8]. In the model of a basal ganglia function 
developed by Alexander and Crutcher [9], motor output 
was found to be modulated by a cortico-basal ganglia-
thalamocortical circuit, which contains a direct and an 
indirect pathway. Direct pathway lesions typically lead 
to hypokinetic movement disorders such as Parkinson-
ism, and it is known that indirect pathway lesions lead 
to hyperkinetic movement disorders such as dystonia. In 
this respect, it is known that CP patients with secondary 
dystonia often have lesions in the striatum, primarily in 
the putamen. The putamen forms numerous connections 
with external globus pallidus (GPe) and the subthalamic 
nucleus. Of those, it is shown that the GABAergic pro-
jections of the putamen have an inhibitory effect on the 
subthalamic nucleus. Damage to this inhibitory pathway, 
such as a perinatal insult to the putamen, can result in an 
excessive output from the subthalamic nucleus leading to 
an abnormal increase in involuntary motor movements 
or hyperkinesia. In order to inhibit the overly stimulated 
motor output, a continuous infusion of ITB targets the 
GABAergic projections in the basal ganglia. In addition, 
the position of the ITB catheter tip can affect the resulting 
dystonia control [10]. In this case, the ITB catheter was 
placed at the level of T5, and this placement resulted in a 
high efficacy of ITB for generalized dystonia and spastic-
ity in the patient’s neck and upper extremities.
This patient showed improvement in pain, dystonia, 
and functional level after the use of the ITB pump im-
plantation as compared with DBS. Namely, it is noted 
that the ITB treatment improved the scores as compared 
to the pre-ITB treatment state (post-DBS 72 months). 
Since the patient showed mild impairment in a stair 
climbing item of the MBI due to reduced muscle tone in 
her lower extremities, we gradually decreased the ITB in-
fusion dose from 140 µg to 115 µg through the time of the 
regular follow-up in outpatient clinics.
We hypothesize that there may be two important rea-
sons why ITB therapy was more effective for this patient 
as compared with DBS. First, this patient showed dysto-
nia and spasticity concurrently, which represents a mixed 
type of condition result. Second, the noted dystonic 
movement in this CP patient who had a functional or 
structural encephalopathy resulting from developmen-
tal abnormalities is classified as a secondary dystonia. 
Therefore, DBS may not be effective in these patients for 
the reason that the brain circuitry is not intact. In case a 
DBS treatment shows no effect or functional deteriora-
tion in patients with secondary dystonia such as CP, an 
ITB treatment can be considered for the treatment of dys-
tonia.
In conclusion, we report a patient with dystonic CP, 
who received the ITB pump implantation long after the 
DBS, who did not respond to a course of oral medications 
and botulinum toxin treatment, and who was treated 
initially with DBS and subsequently with ITB therapy. 
The ITB therapy resulted in a remarkable improvement 
of dystonia, functional level, pain, and satisfaction in the 
overall health status as compared with DBS in a patient 
with dystonic CP mixed with spasticity.
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